Bicycle Therapeutics PLC Sponsored ADR $BCYC Shares Sold by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. lessened its holdings in shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) by 70.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 41,368 shares of the company’s stock after selling 97,293 shares during the quarter. Harbor Capital Advisors Inc. owned 0.06% of Bicycle Therapeutics worth $320,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Ausdal Financial Partners Inc. bought a new position in Bicycle Therapeutics during the 2nd quarter valued at $70,000. Sei Investments Co. bought a new position in shares of Bicycle Therapeutics during the second quarter worth about $74,000. Virtus Investment Advisers LLC grew its stake in Bicycle Therapeutics by 32.6% in the second quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock worth $75,000 after purchasing an additional 2,659 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in Bicycle Therapeutics in the second quarter valued at about $86,000. Finally, State of Tennessee Department of Treasury acquired a new stake in Bicycle Therapeutics during the second quarter valued at approximately $100,000. 86.15% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 3,231 shares of the stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $8.41, for a total value of $27,172.71. Following the completion of the transaction, the chief executive officer directly owned 475,310 shares of the company’s stock, valued at $3,997,357.10. This represents a 0.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders sold 8,527 shares of company stock valued at $71,738. Corporate insiders own 8.50% of the company’s stock.

Wall Street Analysts Forecast Growth

BCYC has been the subject of a number of research analyst reports. Citigroup reiterated an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday, October 31st. Royal Bank Of Canada reissued a “sector perform” rating and set a $11.00 target price (down from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Truist Financial started coverage on shares of Bicycle Therapeutics in a research report on Monday, November 24th. They set a “hold” rating and a $10.00 price objective for the company. Finally, Citizens Jmp increased their price objective on shares of Bicycle Therapeutics from $10.00 to $12.00 and gave the stock a “market outperform” rating in a research note on Friday, October 31st. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $19.73.

Bicycle Therapeutics Stock Down 0.6%

Shares of NASDAQ:BCYC opened at $6.78 on Tuesday. The company’s 50-day moving average price is $7.12 and its 200 day moving average price is $7.46. The company has a market cap of $470.33 million, a PE ratio of -1.87 and a beta of 1.47. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $6.03 and a fifty-two week high of $15.47.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, October 30th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.24. The firm had revenue of $11.73 million during the quarter, compared to analysts’ expectations of $8.25 million. Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. As a group, equities analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current year.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.